BioSpace News Archive

Avanos Medical, Inc. reported third quarter 2019 results and revised its full-year 2019 outlook.

Sojournix announces that Daniel Grau, Chief Executive Officer of Sojournix, will present at the Stifel 2019 Healthcare Conference on Tuesday November 9 at 10:20m ET at the Lotte New York Palace Hotel in New York.

MYOS RENS Technology Inc., an advanced nutrition company and the owner of Fortetropin®, the unique proprietary bioactive composition made from fertilized egg yolks clinically proven to help build lean muscle, announced the expansion of its animal health business with the launch of “Veterinarian Strength Myos Canine Muscle Formula®.”

R&D Day presentation discloses four research programs demonstrating the transformative science, urgency and efficiency underpinning the company’s integrated precision medicine platform

Ongoing Phase 1/2a Study of CD19 CAR-NK with Pivotal Study Expected to Enroll Patients in 2021

Third Quarter 2019 GAAP Net Income of $8.9 million

Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.

2020 Payment Rules from the Centers for Medicare and Medicaid Services Bring CCM Therapy to Heart Failure Patients in the Outpatient Setting

Trial Data to Support Regulatory Submission to U.S. Food and Drug Administration

First CANbridge Oncology Targeted Therapy to be Approved